GM1 Gangliosidosis Treatment Market
- 2026 年市場規模
- USD 194.2 Mn
- 2033 年預估規模
- USD 1,658.9 Mn
- 年複合成長率 CAGR
- 36.7%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
GM1 Gangliosidosis Treatment Market, By Product Type (LYS-GM101, PBGM01, AXO-AAV-GM1), By Disease Type (Type 1 GM1 Gangliosidosis, Type 2 GM1 Gangliosidosis, Type 3 GM1 Gangliosidosis), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East and Africa )
報告摘要
GM1 gangliosidosis is a progressive neurological genetic disorder mainly caused by the absence of a vital enzyme known as beta-galactosidase (GLB1). Without GLB1, a fatty substance called GM1 gangliosidosis accumulates in cells, and nerve cells of the brain. GM1 gangliosidosis is one of the 50 genetically inherited disorders known as lysosomal storage diseases. Currently, there is no treatment or cure for treatment of GM1 gangliosidosis.
Market Dynamics
Key players are focusing on strategic agreements in order to expand their presence in the market. For instance, in May 2017, Lysogene entered a strategic manufacturing agreement with Brammer Bio, a viral gene and cell therapy manufacturer. The agreement is expected to help Brammer Bio manufacture LYS-GM101, an AAVrh10- based gene therapy for the treatment of GM1 gangliosidosis.
Key features of the study
• This report studies the current scenario as well as the future potential of the global GM1 gangliosidosis market. The market for GM1 gangliosidosis is segmented on the basis of product type, disease type, and region.
• This report provides in-depth analysis of the global GM1 gangliosidosis market, and provides market size (USD Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2026–2033)
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by the leading players.
• It profiles leading players in the global GM1 gangliosidosis market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and future plans
• Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future market expansion and marketing tactics
• The global GM1 gangliosidosis market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
• Stakeholders would greatly benefit in decision making through various strategy matrices used in analyzing the global GM1 gangliosidosis market
Gm1 Gangliosidosis Treatment Market Segmentation
• By Product Type
o LYS-GM101
o PBGM01
o AXO-AAV-GM1
• By Disease Type
o Type 1 GM1 Gangliosidosis
o Type 2 GM1 Gangliosidosis
o Type 3 GM1 Gangliosidosis
• Global Gm1 Gangliosidosis Treatment Market, By Region
o North America
U.S.
Canada
o Latin America
Brazil
Mexico
Argentina
Rest of Latin America
o Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC
Israel
Rest of Middle East
o Africa
South Africa
Central Africa
North Africa
• Competitive Landscape
• Company Profiles
o Axovant Gene Therapies Ltd.
o Passage Bio
o Lysogene
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Product Type
Market Snapshot, By Disease Type
Market Snapshot, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Drivers
o Restraints
o Market Opportunities
o Impact Analysis
o Pipeline Analysis
o Regulatory Scenario
o Key Development
o Epidemiology
o Primary Research Insights
Patient Insights
Physician Insights
Manufacturer Insights
4. Global GM1 Glangliosidosis Treatment Market, By Product Type, 2021-2033 (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022–2033
Segment Trends
o LYS-GM101
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
o PBGM01
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
o AXO-AAV-GM1
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
5. Global GM1 Glangliosidosis Treatment Market, By Disease Type, 2021–2033 (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022–2033
Segment Trends
o Type 1 GM1 Gangliosidosis
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
o Type 2 GM1 Gangliosidosis
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
o Type 3 GM1 Gangliosidosis
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
6. Global GM1 Glangliosidosis Treatment Market, By Region, 2021–2033 (USD Mn)
o Introduction
Market Share Analysis, By Country, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Countries, 2022–2033
o North America
Introduction
Market Size and Forecast, By Product Type, 2021–2033 (USD Mn)
Market Size and Forecast, By Disease Type, 2021–2033 (USD Mn)
Market Size and Forecast, By Country, 2021–2033 (USD Mn)
o U.S.
o Canada
o Europe
Introduction
Market Size and Forecast, By Product Type, 2021–2033 (USD Mn)
Market Size and Forecast, By Disease Type, 2021–2033 (USD Mn)
Market Size and Forecast, By Country, 2021–2033 (USD Mn)
o Germany
o U.K.
o Spain
o France
o Italy
o Russia
o Rest of Europe
o Latin America
Introduction
Market Size and Forecast, By Product Type, 2021–2033 (USD Mn)
Market Size and Forecast, By Disease Type, 2021–2033 (USD Mn)
Market Size and Forecast, By Country, 2021–2033 (USD Mn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Asia Pacific
Introduction
Market Size and Forecast, By Product Type, 2021–2033 (USD Mn)
Market Size and Forecast, By Disease Type, 2021–2033 (USD Mn)
Market Size and Forecast, By Country, 2021–2033 (USD Mn)
o China
o India
o Japan
o Australia
o South Korea
o ASEAN
o Rest of Asia Pacific
o Middle East
Introduction
Market Size and Forecast, By Product Type, 2021–2033 (USD Mn)
Market Size and Forecast, By Disease Type, 2021–2033 (USD Mn)
Market Size and Forecast, By Country, 2021–2033 (USD Mn)
o GCC Countries
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, By Product Type, 2021–2033 (USD Mn)
Market Size and Forecast, By Disease Type, 2021–2033 (USD Mn)
Market Size and Forecast, By Country, 2021–2033 (USD Mn)
o Central Africa
o South Africa
o North Africa
7. Competitive Landscape
o Company Profiles
Axovant Gene Therapies Ltd.
o Company Overview
o Clinical Trial Phase Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Passage Bio
o Company Overview
o Clinical Trial Phase Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Lysogene
o Company Overview
o Clinical Trial Phase Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
*Browse 16 market data tables and 16 figures on “GM1 Glangliosidosis Treatment Market– Global forecast to 2033”.
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們